Pharmacogenomics and affective disorders: origins, foundations and clinical applicability
DOI:
https://doi.org/10.25118/2763-9037.2012.v2.889Keywords:
affective disorders, pharmacogenetics, pharmacogenomics, antidepressantsAbstract
The possibility of personalized treatment (adapting therapies based on each patient's genetic profile) is one of the promising aspects of pharmacotherapy for affective disorders. Identifying the relationship between genotype and response to antidepressants, including both the therapeutic effect and the profile of adverse effects, may profoundly change medical practice. In this update article, we seek to review the foundations of this field of research called pharmacogenetics or pharmacogenomics applied to affective disorders, starting from the genetic foundations of affective disorders, moving on to current knowledge about genes associated with response to antidepressants, and pointing out possible reasons for the still inconsistent findings of studies in this field.
Downloads
Metrics
References
Trivedi MH, Rush a J, Wisniewski SR, Nierenberg A a, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. The American journal of Psychiatry,.2006;163:28–40. DOI: https://doi.org/10.1176/appi.ajp.163.1.28
Malhotra A, Murphy G. Pharmacogenetics of psychotropic drug response. The American Journal of Psychiatry, 2004;161:780–96. DOI: https://doi.org/10.1176/appi.ajp.161.5.780
Franchini L, Serretti A, Gasperini M, Smeraldi E. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. Journal of Psychiatric Research, 1998;32:255–9. DOI: https://doi.org/10.1016/S0022-3956(98)00004-1
O’Reilly RL, Bogue L, Singh SM. Pharmacogenetic response to antidepressants in a multicase family with affective disorder. Biological Psychiatry, 1994;36:467–71. DOI: https://doi.org/10.1016/0006-3223(94)90642-4
Mcguffin P. Genetic Research in Psychiatry. In: Psychiatry as a Neuroscience. 2002. p. 1–27. DOI: https://doi.org/10.1002/0470846461.ch1
Galton F. Hereditary genius. London: McMillan, 1892.
McGuffin P. Genomics and behavior: Toward Behavioral Genomics. Science, 2001;291:1232–49. DOI: https://doi.org/10.1126/science.1057264
Van Praag H. Mood and Anxiety Disorders. A diagnostic pleonasm. In: Nutt D, Ballenger JC, editores. Anxiety Disorders. Oxford: Blackwell Science, 2003.
Roses a D. Pharmacogenetics and future drug development and delivery. Lancet, 2000;355:1358–61. DOI: https://doi.org/10.1016/S0140-6736(00)02126-7
Hettema JM. What is the genetic relationship between anxiety and depression? American journal of medical genetics. Part C, Seminars in Medical Genetics, 2008;148C:140–6. DOI: https://doi.org/10.1002/ajmg.c.30171
Huezo-Diaz P, Tandon K, Aitchison KJ. The genetics of depression and related traits. Current Psychiatry Reports, 2005;7:117–24. DOI: https://doi.org/10.1007/s11920-005-0008-5
Kupfer DJ, Frank E, Phillips ML. Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet, 2011;379:1045–55. DOI: https://doi.org/10.1016/S0140-6736(11)60602-8
Mrazek D. Psychiatric Pharmacogenomics. New York: Oxford University Press; 2010. DOI: https://doi.org/10.1093/med/9780195367294.001.0001
Kirchheiner J, Brøsen K, Dahl ML, Gram LF, Kasper S, Roots I, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatrica Scandinavica, 2001;104:173–92. DOI: https://doi.org/10.1034/j.1600-0447.2001.00299.x
Weinshilboum R. Inheritance and drug response. The New England journal of medicine, 2003;348:529–37. DOI: https://doi.org/10.1056/NEJMra020021
Berg A, Piper M, Armstrong K, Botkin J, Haddow J. Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genetics in Medicine, 2007;9:819–25. DOI: https://doi.org/10.1097/GIM.0b013e31815bf9a3
Lesch KP, Bengel D, Heils a, Sabol SZ, Greenberg BD, Petri S, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science, 1996;274:1527–31. DOI: https://doi.org/10.1126/science.274.5292.1527
Serretti a, Kato M, De Ronchi D, Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Molecular psychiatry, 2007;12:247–57. DOI: https://doi.org/10.1038/sj.mp.4001926
Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Molecular psychiatry, 2010;15:473–500. DOI: https://doi.org/10.1038/mp.2008.116
Porcelli S, Drago A, Fabbri C, Gibiino S, Calati R, Serretti A. Pharmacogenetics of antidepressant response. Journal of psychiatry & neuroscience , 2011;36: 87–113. DOI: https://doi.org/10.1503/jpn.100059
Suarez-kurtz G. Pharmacogenomics in Admixed Populations. Austin: Landes Bioscience, 2007. DOI: https://doi.org/10.1201/9781498713795
Downloads
Published
How to Cite
Conference Proceedings Volume
Section
License
Copyright (c) 2012 Vitor de Mello Netto
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Debates em Psiquiatria allows the author (s) to keep their copyrights unrestricted. Allows the author (s) to retain their publication rights without restriction. Authors should ensure that the article is an original work without fabrication, fraud or plagiarism; does not infringe any copyright or right of ownership of any third party. Authors should also ensure that each one complies with the authorship requirements as recommended by the ICMJE and understand that if the article or part of it is flawed or fraudulent, each author shares responsibility.
Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) - Debates em Psiquiatria is governed by the licencse CC-By-NC
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
